OGN Organon & Co.
Pharmaceutical Preparations · NYSE · SEC CIK 1821825 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.2%
TTM net income YoY-57.5%
TTM EPS YoY-59.2%
Revenue 3-yr CAGR-0.3%
Net income 3-yr CAGR-28.6%
Margins
Gross margin53.1%
Operating margin—
Net margin3.5%
FCF margin11.1%
EBITDA margin—
Returns
ROE20.3%
ROA1.6%
ROIC (approx.)—
Asset turnover0.45x
Leverage & solvency
Liabilities / assets91.1%
Debt / equity7.17x
Current ratio2.02x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.96x
Accruals ratio-4.7%
Payout ratio9.4%
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.57B | $1.56B | $1.46B | $1.51B | $1.60B | $1.59B | $1.51B | $1.59B |
| Cost of revenue | $705.00M | $711.00M | $677.00M | $766.00M | $745.00M | $720.00M | $672.00M | $696.00M |
| Gross profit | $869.00M | $847.00M | $783.00M | $741.00M | $857.00M | $874.00M | $841.00M | $896.00M |
| R&D expense | $83.00M | $90.00M | $93.00M | $91.00M | $84.00M | $95.00M | $96.00M | $130.00M |
| SG&A expense | $421.00M | $434.00M | $424.00M | $433.00M | $415.00M | $453.00M | $420.00M | $470.00M |
| Interest expense | $106.00M | $108.00M | $111.00M | $121.00M | $128.00M | $131.00M | $124.00M | $132.00M |
| Pretax income | $255.00M | $183.00M | $213.00M | -$148.00M | $243.00M | $229.00M | $101.00M | $129.00M |
| Income tax | $91.00M | $75.00M | $67.00M | $57.00M | $83.00M | $84.00M | $14.00M | $20.00M |
| Net income | $164.00M | $108.00M | $146.00M | -$205.00M | $160.00M | $145.00M | $87.00M | $109.00M |
| EPS (basic) | 0.62 | 0.41 | 0.56 | — | 0.61 | 0.56 | 0.34 | — |
| EPS (diluted) | 0.60 | 0.40 | 0.55 | — | 0.61 | 0.56 | 0.33 | — |
| Dividends declared per share | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.28 | 0.28 |
| Weighted avg. shares (diluted) | 272.38M | 270.45M | 262.90M | — | 260.65M | 260.16M | 261.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.46B | $1.13B | $1.12B | $574.00M | $672.00M | $599.00M | $547.00M | $675.00M |
| Receivables | $1.48B | $1.49B | $1.38B | $1.33B | $1.48B | $1.48B | $1.46B | $1.36B |
| Inventory | $1.35B | $1.35B | $1.37B | $1.41B | $1.49B | $1.45B | $1.36B | $1.32B |
| Current assets | $5.37B | $5.11B | $4.93B | $4.35B | $4.70B | $4.62B | $4.37B | $4.35B |
| PP&E, net | $1.29B | $1.28B | $1.28B | $1.30B | $1.29B | $1.27B | $1.20B | $1.17B |
| Goodwill | $4.15B | $4.15B | $4.15B | $4.15B | $4.68B | $4.68B | $4.68B | $4.68B |
| Intangibles | $1.06B | $1.11B | $1.10B | $1.13B | $1.34B | $1.36B | $1.42B | $1.41B |
| Total assets | $13.40B | $13.18B | $13.00B | $12.87B | $13.55B | $13.50B | $13.16B | $13.10B |
| Current liabilities | $2.65B | $2.62B | $2.50B | $2.39B | $2.68B | $2.80B | $2.62B | $2.72B |
| Short-term debt | $69.00M | $74.00M | $16.00M | $16.00M | $45.00M | $115.00M | $20.00M | $20.00M |
| Long-term debt | $8.48B | $8.48B | $8.55B | $8.63B | $8.78B | $8.78B | $8.94B | $8.86B |
| Total debt | $8.55B | $8.55B | $8.57B | $8.64B | $8.83B | $8.90B | $8.96B | $8.88B |
| Total liabilities | $12.21B | $12.17B | $12.09B | $12.12B | $12.65B | $12.77B | $12.61B | $12.63B |
| Shareholders' equity | $1.19B | $1.01B | $903.00M | $752.00M | $906.00M | $733.00M | $542.00M | $472.00M |
| Net debt | $7.10B | $7.42B | $7.45B | $8.07B | $8.16B | $8.30B | $8.41B | $8.21B |
| Shares outstanding | 262.62M | 262.61M | 262.65M | 260.32M | 259.98M | 259.96M | 257.95M | 257.80M |
| Cash flow statement | ||||||||
| Operating cash flow | $370.00M | $107.00M | $225.00M | $141.00M | $264.00M | $220.00M | $75.00M | $390.00M |
| Capital expenditure | $44.00M | $42.00M | $37.00M | $45.00M | $46.00M | $39.00M | $32.00M | $55.00M |
| Free cash flow | $326.00M | $65.00M | $188.00M | $96.00M | $218.00M | $181.00M | $43.00M | $335.00M |
| Investing cash flow | -$44.00M | -$76.00M | $386.00M | -$65.00M | -$115.00M | -$38.00M | -$172.00M | -$296.00M |
| Financing cash flow | -$5.00M | -$12.00M | -$38.00M | -$187.00M | -$76.00M | -$223.00M | -$75.00M | -$82.00M |
| Depreciation & amortization | $34.00M | $34.00M | $39.00M | $46.00M | $40.00M | $36.00M | $34.00M | $34.00M |
| Stock-based compensation | $21.00M | $25.00M | $19.00M | $7.00M | $24.00M | $22.00M | $24.00M | $26.00M |
| Dividends paid | $5.00M | $6.00M | $5.00M | $4.00M | $3.00M | $10.00M | $71.00M | $74.00M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.